Intelligent Bio Solutions (INBS) risk factors
Item 1A of every Intelligent Bio Solutions Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors57 risks5 new1 dropped11 reworded
Nasdaq compliance remains a financing and liquidity risk despite the 2025 reverse split restoring the $1 minimum bid price.
Filed Aug 19, 2026 - FY2025 10-K risk factors53 risks5 new9 dropped13 reworded
The company faces delisting risks, material weaknesses in financial controls, and a $2,172,108 payable to the Australian Government. Net loss widened to $10,568,733 for the fiscal year ended June 30, 2025. Intellectual property risks expanded due to limited foreign protections and new U.S. tax and tariff laws.
Filed Aug 15, 2025 - FY2024 10-K risk factors57 risks
This is an initial filing with no prior year risk factors. Risk is dominated by going concern doubts, reliance on unlaunched products, single-source suppliers, and strict regulatory and intellectual property dependencies.
Filed Sep 18, 2024